Aquestive Therapeutics (AQST) Cost of Revenue (2017 - 2026)

Aquestive Therapeutics has reported Cost of Revenue for 10 years, with the latest figure at $4.0 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 11.93% year-over-year to $4.0 million in Q2 2026; TTM through Jun 2026 was $17.8 million, a 3.83% increase from a year earlier, with the FY2025 full-year figure at $18.6 million, up 3.82% from the prior year.
• Cost of Revenue was $4.0 million for Q2 2026 at Aquestive Therapeutics, up from $3.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $6.6 million in Q2 2023, with the low at $3.5 million in Q1 2026.
• Average Cost of Revenue over 5 years is $4.7 million, with a median of $4.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue soared 57.61% in 2022, then slumped 31.6% in 2024.
• Over 5 years, Cost of Revenue stood at $5.3 million in 2022, then gained by 3.34% to $5.5 million in 2023, then fell by 17.55% to $4.5 million in 2024, then rose by 29.12% to $5.8 million in 2025, then sank by 31.17% to $4.0 million in 2026.
• The last three Cost of Revenue figures came in at $4.0 million (Q2 2026), $3.5 million (Q1 2026), and $5.8 million (Q4 2025), per Business Quant data.